Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus ACUVUE THERAVISION WITH KETOTIFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus ACUVUE THERAVISION WITH KETOTIFEN.
ACTAHIST vs ACUVUE THERAVISION WITH KETOTIFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
1.34 mg (one capsule) orally twice daily.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer